Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.
Pharm Stat
; 11(1): 8-13, 2012.
Article
en En
| MEDLINE
| ID: mdl-21308974
ABSTRACT
In 2008, this group published a paper on approaches for two-stage crossover bioequivalence (BE) studies that allowed for the reestimation of the second-stage sample size based on the variance estimated from the first-stage results. The sequential methods considered used an assumed GMR of 0.95 as part of the method for determining power and sample size. This note adds results for an assumed GMR = 0.90. Two of the methods recommended for GMR = 0.95 in the earlier paper have some unacceptable increases in Type I error rate when the GMR is changed to 0.90. If a sponsor wants to assume 0.90 for the GMR, Method D is recommended. Copyright © 2011 John Wiley & Sons, Ltd.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Proyectos de Investigación
/
Preparaciones Farmacéuticas
/
Estudios Cruzados
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Año:
2012
Tipo del documento:
Article